DC_AC50

Confirm delete?

DC_AC50

Zoom

Cat No: 19283

Biochemicals - More Biochemicals

DC_AC50 is an inhibitor of the copper-trafficking proteins Atox1 and CCS.{53558} It binds to purified Atox1 and CCS (Kds = 6.8 and 8.2 μM, respectively) and inhibits the interaction between Atox1 and domain 4 of the Cu+-ATPase ATP7B in the presence of...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

3-amino-N-(2-bromo-4,6-difluorophenyl)-6,7-dihydro-5H-cyclopenta[b]thieno[3,2-e]pyridine-2-carboxamide

Correlated keywords:

DCAC50 DC-AC-50 DCAC-50 Atox-1 ATP-7B H-1299 K-562 MDAMB-231 MDAMB231 212-LN PIG-1 MCF10A

Product Overview:
DC_AC50 is an inhibitor of the copper-trafficking proteins Atox1 and CCS.{53558} It binds to purified Atox1 and CCS (Kds = 6.8 and 8.2 μM, respectively) and inhibits the interaction between Atox1 and domain 4 of the Cu+-ATPase ATP7B in the presence of zinc in a FRET-based assay when used at a concentration of 100 μM. DC_AC50 increases copper and reactive oxygen species (ROS) levels and decreases COX activity and lipid biosynthesis in H1299 cells when used at a concentration of 10 μM. It inhibits the proliferation of H1299, K562, MDA-MB-231, and 212LN cancer cells, but not PIG1, HDF, HaCaT, or MCF-10A cells, in a concentration-dependent manner. DC_AC50 (100 mg/kg per day) reduces tumor growth in an H1299 mouse xenograft model.

Size	1 mg
Shipping	dry ice
CAS Number	497061-48-0
Molecular Formula	C₁₇H₁₂BrF₂N₃OS
SMILES	NC1=C(C(NC2=C(F)C=C(F)C=C2Br)=O)SC3=NC4=C(CCC4)C=C31
Molecular Weight	424,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.